Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Respirerx Pharmaceuticals Inc (RSPI)

Respirerx Pharmaceuticals Inc (RSPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 697
  • Shares Outstanding, K 774,682
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,100 K
  • 60-Month Beta 0.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RSPI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 11/17/23
  • Latest Earnings Date 05/27/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0008 +12.50%
on 04/23/24
0.0010 -10.00%
on 04/19/24
-0.0002 (-18.18%)
since 03/26/24
3-Month
0.0007 +28.57%
on 03/08/24
0.0025 -64.00%
on 02/02/24
-0.0007 (-43.75%)
since 01/26/24
52-Week
0.0006 +50.00%
on 10/30/23
0.0191 -95.29%
on 05/30/23
-0.0019 (-67.86%)
since 04/26/23

Most Recent Stories

More News
RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition

Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics.

Glen Rock, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus

Glen Rock, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the discovery...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol

Glen Rock, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality

Glen Rock, N.J., March 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain

Glen Rock, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase™

Glen Rock, N.J., Dec. 14, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), with a mission to...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81

Glen Rock, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81

Glen Rock, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery...

RSPI : 0.0009 (unch)
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury

Glen Rock, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the...

OTC.VN : 0.345 (unch)
RSPI : 0.0009 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company which focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, drug-induced respiratory depression and other brain- mediated breathing disorders. The company's drug platforms comprises of ampakines...

See More

Key Turning Points

3rd Resistance Point 0.0009
2nd Resistance Point 0.0009
1st Resistance Point 0.0009
Last Price 0.0009
1st Support Level 0.0009
2nd Support Level 0.0009
3rd Support Level 0.0009

See More

52-Week High 0.0191
Fibonacci 61.8% 0.0120
Fibonacci 50% 0.0099
Fibonacci 38.2% 0.0077
Last Price 0.0009
52-Week Low 0.0006

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar